Select therapeutic use:
Indications for FUZEON:
Treatment of HIV-1 infection, in combination with other antiretroviral agents, in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Give by SC inj into upper arm, anterior thigh, or abdomen (not into moles, scar tissue, bruises, or navel). Rotate inj sites. >16yrs: 90mg twice daily.
<6yrs: limited data available. Give by SC inj into upper arm, anterior thigh, or abdomen (not into moles, scar tissue, bruises, or navel). Rotate inj sites. 6–16yrs: 2mg/kg twice daily; max 90mg twice daily.
Discontinue if hypersensitivity occurs; do not rechallenge. Instruct patients on proper use of Biojector 2000 needle-free device. Monitor for pneumonia (esp. if low initial CD4 cell count, high initial viral load, IV drug use, history of lung disease, or smoker). Coagulation disorders. Renal insufficiency (CrCl <35mL/min). Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Increased risk of post-injection bleed with concomitant anticoagulants. May cause false (+) ELISA test for HIV.
Local inj site reactions, diarrhea, nausea, fatigue; pneumonia, hypersensitivity reactions, immune reconstitution syndrome, autoimmune disorders.
Register pregnant patients exposed to enfuvirtide by calling (800) 258-4263.
Kit—1 (60 vials w. supplies)